Brief: Galecto Completes Enrollment In Global Trial Of GB0139 for Treatment of IPF

Damora Therapeutics

26/04/2022 13:39

April 26 (Reuters) - Galecto Inc  GLTO.O :
    * GALECTO COMPLETES ENROLLMENT IN GLOBAL PHASE 2B GALACTIC-1
TRIAL
OF GB0139 FOR THE TREATMENT OF IPF
    * GALECTO INC - GALACTIC-1 TRIAL ON TRACK TO DELIVER
TOP-LINE
RESULTS IN MID-2023

Source text for Eikon:  ID:nGNX2PNNdp 
Further company coverage:  GLTO.O 

 ((Reuters.Briefs@thomsonreuters.com;))